C-TEIJ3D cell expansion, placenta-derived cell therapy, cell-based manufacturing
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Pluri Inc (prev Pluristem) 3D cell expansion, placenta-derived cell therapy, cell-based manufacturing
Pluri uses patented three-dimensional cell expansion platforms to grow plant, animal and human cells in an efficient and cost-effective process. Its health pipeline includes PLX-PAD and PLX-R18 placenta-derived, mesenchymal-like adherent stromal cell products. The company also applies its platform beyond pharma, including food tech, agri-tech and CDMO services.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Pluri Inc (prev Pluristem) — Near-term readout · Bottom quartile. Derived deterministically from 11 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic